Equities

Integrum AB

Integrum AB

Actions
  • Price (USD)0.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Integrum AB is a Sweden-based company within healthcare sector. It provides systems for bone-anchored prostheses for individuals with amputations. The Company’s solutions comprise OPRA Implant System, neural prosthetics, phantom limb pain treatment and prosthetic components. The OPRA implant system is based on osseointegration, enabling the direct connection of an artificial limb to the skeleton. The neural prosthetics technology implies ability to directly connect bionic prostheses to the patient’s bone, nerves, and muscles. A method for limb pain treatment implies motor execution of the phantom limb as a treatment, which is aided by machine learning, augmented and virtual reality. The Company provides a variety of prosthetic components required to connect the OPRA Implant System to external prostheses.

  • Revenue in SEK (TTM)104.12m
  • Net income in SEK4.17m
  • Incorporated1990
  • Employees36.00
  • Location
    Integrum ABKrokslatts Fabriker 50MOELNDAL 431 37SwedenSWE
  • Phone+46 317601060
  • Fax+46 31155260
  • Websitehttps://integrum.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.